HIG2 Antibodies

Santa Cruz Biotechnology features a diverse variety of HIG2 monoclonal antibodies for research focused on understanding HIG2 protein functions. HIG2 Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). HIG2, or Hypoxia-Inducible Gene 2, plays a critical role in cellular responses to hypoxic conditions, influencing processes such as cell survival, proliferation, and metabolism. HIG2 expression increases in response to low oxygen levels, making it particularly relevant in cancer biology and other diseases where hypoxia is a key feature. Understanding HIG2 function is essential for developing therapeutic strategies targeting hypoxia-related pathways. Researchers worldwide rely on HIG2 monoclonal antibodies to investigate cellular responses under hypoxic conditions. Current studies focus on how HIG2 influences tumor growth and metastasis in various cancer types. Ongoing research explores HIG2's potential as a therapeutic target in diseases characterized by oxygen deficiency. Santa Cruz Biotechnology monoclonal antibodies enable researchers to advance scientific understanding of hypoxia-related cellular mechanisms and potential therapeutic applications.